BEAUTYFARM MED issued a profit warning, expecting a mid-term net profit of no less than 17 million yuan, with a year-on-year growth of no less than 35%

According to the announcement from BEAUTYFARM MED (02373), the group expects to achieve the following financial performance for the six months ending June 30, 2025: revenue of no less than RMB 1.45 billion, an increase of no less than 27% compared to the same period in 2024; adjusted net profit of no less than RMB 17.5 million, an increase of no less than 33% compared to the same period in 2024; and net profit of no less than RMB 17 million, an increase of no less than 35% compared to the same period in 2024.

Since its establishment thirty years ago, the group has consistently led the development of the beauty and health industry and has now become one of the largest beauty and health management service platforms in China. Despite the complex and changing environment in the industry, it has maintained a good momentum of performance growth. The board believes that the performance improvement is mainly due to the following reasons: continuous refinement of the "Double Beauty + Double Healthcare" business model, an increase in the proportion of high-margin business revenue, which drives continuous optimization of the company's revenue structure and promotes an increase in gross profit margin; and the firm execution of the "internal growth + external expansion" dual-drive strategy, which drives the company's scale growth and continuous increase in market share, while the scale effect promotes a continuous increase in net profit margin